-- Record revenue of $9M in 4QFY22; Increase of 191% over 4QFY21 -- BioXp ® Revenue increased by 131% to $3M, in 4QFY22 over 4QFY21 -- Successful achievement of first technical milestone with Pfizer leveraging Telesis Bio’s SOLA platform for enzymatic DNA synthesis technology SAN DIEGO, Jan.